NO20012927D0 - Nye ligander av nukle¶r reseptor - Google Patents

Nye ligander av nukle¶r reseptor

Info

Publication number
NO20012927D0
NO20012927D0 NO20012927A NO20012927A NO20012927D0 NO 20012927 D0 NO20012927 D0 NO 20012927D0 NO 20012927 A NO20012927 A NO 20012927A NO 20012927 A NO20012927 A NO 20012927A NO 20012927 D0 NO20012927 D0 NO 20012927D0
Authority
NO
Norway
Prior art keywords
nuclear receptor
new ligands
ligands
new
nuclear
Prior art date
Application number
NO20012927A
Other languages
English (en)
Other versions
NO20012927L (no
Inventor
Gakuzo Tamura
Kunio Ando
Junji Magae
Takafumi Uchida
Original Assignee
Nuclear Receptor Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclear Receptor Res Ltd filed Critical Nuclear Receptor Res Ltd
Publication of NO20012927D0 publication Critical patent/NO20012927D0/no
Publication of NO20012927L publication Critical patent/NO20012927L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20012927A 1998-12-14 2001-06-13 Nye ligander av nukle¶r reseptor NO20012927L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP37790598 1998-12-14
PCT/JP1999/007012 WO2000035867A1 (fr) 1998-12-14 1999-12-14 Nouveaux ligands d'un recepteur nucleaire

Publications (2)

Publication Number Publication Date
NO20012927D0 true NO20012927D0 (no) 2001-06-13
NO20012927L NO20012927L (no) 2001-08-14

Family

ID=18509242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012927A NO20012927L (no) 1998-12-14 2001-06-13 Nye ligander av nukle¶r reseptor

Country Status (11)

Country Link
US (1) US6605639B1 (no)
EP (1) EP1142870A1 (no)
KR (1) KR20010093825A (no)
CN (1) CN1226290C (no)
AU (1) AU1797700A (no)
BR (1) BR9916821A (no)
CA (1) CA2355299A1 (no)
MX (1) MXPA01005998A (no)
NO (1) NO20012927L (no)
TR (1) TR200102219T2 (no)
WO (1) WO2000035867A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366281A1 (en) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Novel ligands of nuclear receptors ppar's
EP1481670A4 (en) * 2002-01-31 2005-07-13 Arigen Inc PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF A MULTIFACTOR SYNDROME
JP2005527495A (ja) 2002-02-08 2005-09-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 治療化合物
ATE513807T1 (de) * 2003-02-24 2011-07-15 Nrl Pharma Inc Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2013059606A1 (en) 2011-10-21 2013-04-25 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
KR102051693B1 (ko) 2012-05-29 2019-12-03 가부시키가이샤 미토콘도리아 겐큐쇼 디히드로오로토산 탈수소효소 억제제
JP6386713B2 (ja) * 2013-10-03 2018-09-05 国立大学法人千葉大学 脳循環障害の予防剤および/または治療剤
JP7102006B2 (ja) * 2017-05-18 2022-07-19 達雄 星野 アスコクロリン誘導体を用いた併用療法
JP7267198B2 (ja) * 2017-08-31 2023-05-01 株式会社 資生堂 レチノイドの副作用に対する感受性の決定方法
CN111050759A (zh) 2017-09-15 2020-04-21 雀巢产品有限公司 用于预防和治疗神经障碍的杂萜化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995061A (en) * 1974-04-09 1976-11-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition and method of using the same
AU493677B2 (en) * 1975-02-28 1976-09-02 Okada Masashi Pharmaceutical composition for arteriosclerosis
US4500544A (en) * 1981-09-10 1985-02-19 Chugai Seiyaku Kabushiki Kaisha Ascochlorin derivatives, and pharmaceutical composition containing the same
JPH03291220A (ja) * 1990-04-09 1991-12-20 Chugai Pharmaceut Co Ltd アスコクロリン誘導体を有効成分とするCa代謝異常改善剤
EP0983991B1 (en) 1992-04-22 2003-12-17 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
JPH0816057B2 (ja) * 1992-09-10 1996-02-21 田村 學造 グリケイション阻害剤
MX9306629A (es) * 1993-01-11 1994-07-29 Ligand Pharm Inc Compuestos que tienen actividad selectiva para receptores retinoide x, medios para modulacion de procesos mediados pr receptores de retinoide x.
ATE177733T1 (de) 1993-01-11 1999-04-15 Ligand Pharm Inc Verbindungen mit selektiver wirkung fuer retinoid x rezeptoren, und mittel fuer steuerung fuer durch retinoid x rezeptoren bedingte prozesse
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
JP3291220B2 (ja) 1997-04-23 2002-06-10 日本鋼管株式会社 溶融金属用保温材

Also Published As

Publication number Publication date
KR20010093825A (ko) 2001-10-29
WO2000035867A1 (fr) 2000-06-22
BR9916821A (pt) 2001-10-16
CN1334802A (zh) 2002-02-06
CA2355299A1 (en) 2000-06-22
NO20012927L (no) 2001-08-14
CN1226290C (zh) 2005-11-09
TR200102219T2 (tr) 2002-04-22
EP1142870A1 (en) 2001-10-10
AU1797700A (en) 2000-07-03
US6605639B1 (en) 2003-08-12
MXPA01005998A (es) 2002-09-18

Similar Documents

Publication Publication Date Title
NO20012927D0 (no) Nye ligander av nukle¶r reseptor
NO20000226D0 (no) Nye spiroazabicykliske heterocykliske forbindelser
NO964871D0 (no) Nye agonistforbindelser
NO996572L (no) Nye substituerte imidazolforbindelser
NO20000312L (no) Nye forbindelser
NO996278D0 (no) Overvåkning av nettaksess
NO983181L (no) Nye substituerte imidazolforbindelser
NO970374L (no) Nye forbindelser
NO20002787D0 (no) Nye forbindelser
EE9800194A (et) Uued valuvaigistava toimega ühendid
NO20000657L (no) Ikke-steroidale ligander for østrogen reseptor
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
NO20003137D0 (no) Nye bispidinforbindelser med antiarytmisk aktivitet
NO974605L (no) Nye heterosykliske forbindelser
NO20014394L (no) Nye ligander av nukle¶rreseptorer PPARer
FR2759279B3 (fr) Ecran pare-douche
DE59812234D1 (de) Verbundwasserzähler
NO20010860D0 (no) Nye forbindelser
NO20010861D0 (no) Nye forbindelser
NO20022847D0 (no) Nye substituerte tricykliske forbindelser
DE69910997D1 (de) Azabzyclische 5ht1 rezeptor liganden
NO960268D0 (no) Nye dialkoksypyridinylbenzimidazolderivater
NO20005857D0 (no) Nye blandinger
NO981216D0 (no) Nye heterosykliske forbindelser
NO20010584L (no) Nye forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application